Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 18 04:00PM ET
1.63
Dollar change
+0.05
Percentage change
3.16
%
Index- P/E- EPS (ttm)-7.97 Insider Own9.50% Shs Outstand1.66M Perf Week-18.50%
Market Cap2.71M Forward P/E- EPS next Y-1.64 Insider Trans0.45% Shs Float1.51M Perf Month40.52%
Income-8.69M PEG- EPS next Q-0.76 Inst Own15.95% Short Float1.86% Perf Quarter-11.03%
Sales0.00M P/S- EPS this Y64.04% Inst Trans- Short Ratio0.01 Perf Half Y-44.37%
Book/sh1.92 P/B0.85 EPS next Y64.34% ROA-162.69% Short Interest0.03M Perf Year-83.70%
Cash/sh0.19 P/C8.46 EPS next 5Y- ROE-222.76% 52W Range0.76 - 14.00 Perf YTD-12.37%
Dividend Est.- P/FCF- EPS past 5Y-24.85% ROI-371.68% 52W High-88.36% Beta1.53
Dividend TTM- Quick Ratio2.15 Sales past 5Y0.00% Gross Margin- 52W Low113.07% ATR (14)0.44
Dividend Ex-Date- Current Ratio2.15 EPS Y/Y TTM53.74% Oper. Margin0.00% RSI (14)48.30 Volatility16.21% 30.78%
Employees20 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q62.16% Payout- Rel Volume0.08 Prev Close1.58
Sales Surprise- EPS Surprise7.45% Sales Q/Q- EarningsNov 14 BMO Avg Volume4.04M Price1.63
SMA20-4.73% SMA5010.25% SMA200-49.74% Trades Volume315,780 Change3.16%
Date Action Analyst Rating Change Price Target Change
Oct-30-18Initiated Maxim Group Buy $5
Oct-11-18Initiated Dawson James Buy
Mar-01-24 07:00PM
Feb-28-24 09:30AM
Feb-15-24 09:00AM
Feb-13-24 09:15AM
Jan-18-24 08:30AM
09:00AM Loading…
Dec-20-23 09:00AM
Nov-29-23 04:05PM
Nov-14-23 05:02PM
Oct-31-23 08:30AM
Oct-30-23 12:00PM
Oct-25-23 08:00AM
Oct-24-23 04:30PM
Oct-20-23 08:00AM
Oct-19-23 12:00PM
12:00PM
10:30AM Loading…
10:30AM
Oct-18-23 08:00AM
Sep-28-23 07:00AM
Sep-05-23 08:30AM
Aug-28-23 08:30AM
Aug-23-23 08:30AM
Aug-21-23 08:30AM
Aug-04-23 08:30AM
Jul-19-23 09:59AM
Jul-11-23 08:30AM
Jun-01-23 09:00AM
May-12-23 08:30AM
May-10-23 08:30AM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
09:00AM Loading…
Mar-21-23 09:00AM
Mar-08-23 09:00AM
Mar-07-23 01:51PM
10:46AM
08:05AM
Mar-06-23 04:19PM
Mar-02-23 09:00AM
Feb-28-23 05:27AM
Feb-27-23 09:00AM
Feb-24-23 07:00AM
Feb-21-23 09:00AM
Feb-01-23 09:00AM
Dec-01-22 09:55AM
Nov-14-22 08:30AM
Oct-19-22 04:57PM
Sep-26-22 12:43PM
09:00AM
Sep-06-22 10:02AM
09:00AM
Sep-01-22 09:55AM
Aug-29-22 07:19AM
Aug-26-22 07:42AM
Aug-22-22 04:30PM
Aug-16-22 09:15AM
Jul-20-22 07:00AM
06:45AM
Jul-18-22 09:25AM
Jun-28-22 11:49AM
Jun-27-22 09:16AM
Jun-14-22 10:48AM
09:55AM
May-19-22 09:25AM
May-16-22 09:25AM
May-05-22 04:05PM
May-04-22 09:15AM
Apr-06-22 07:47AM
Mar-22-22 09:15AM
Feb-24-22 09:15AM
Feb-16-22 09:26AM
Feb-11-22 09:00AM
Feb-09-22 09:25AM
Jan-24-22 09:25AM
Jan-12-22 09:40AM
Jan-10-22 09:03AM
Dec-22-21 09:25AM
Dec-08-21 09:25AM
Nov-29-21 09:00AM
Nov-17-21 09:42AM
Nov-10-21 09:26AM
Nov-09-21 09:15AM
Nov-03-21 09:10AM
Oct-21-21 01:06PM
10:13AM
09:45AM
Oct-18-21 09:30AM
Oct-05-21 09:25AM
Oct-04-21 04:30PM
Sep-30-21 09:25AM
Sep-28-21 09:49AM
Sep-15-21 10:07AM
Sep-13-21 09:30AM
Sep-07-21 09:00AM
Aug-31-21 09:30AM
Aug-20-21 10:45AM
09:40AM
Aug-12-21 02:50PM
Aug-10-21 09:30AM
Aug-05-21 10:12AM
Jul-29-21 09:30AM
Jul-14-21 02:00PM
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson & William B. Stilley in November 2010 and is headquartered in Charlottesville, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuyler KevinDirectorSep 29 '23Buy2.747001,918700Oct 03 08:54 AM